US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma

PURPOSE: To estimate the budget impact of selinexor, bortezomib, and dexamethasone (XVd) in patients with previously treated multiple myeloma (MM) from the perspective of a private third-party payer and Medicare in the US. METHODS: The introduction of XVd as an option for patients with previously tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Dolph, Mike, Tremblay, Gabriel, Leong, Hoyee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8203300/
https://www.ncbi.nlm.nih.gov/pubmed/34140789
http://dx.doi.org/10.2147/CEOR.S305830

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8203300/
https://www.ncbi.nlm.nih.gov/pubmed/34140789
http://dx.doi.org/10.2147/CEOR.S305830

Ejemplares similares